Picture Credit score: Nemes Laszlo
Zanubrutinib plus venetoclax delivered promising preliminary efficacy leads to newly identified CLL/SLL in individuals with del(17p) and/or TP53 mutations.
The mix of zanubrutinib and venetoclax was related to deep and sturdy responses in individuals with beforehand untreated high-risk power lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and del(17p) and/or TP53 mutations, first outcomes of the SEQUOIA trial confirmed.
Arm D of the SEQUOIA trial (NCT03336333) uncovered 66 individuals with CLL/SLL and del(17p) and/or TP53 mutations to the mix routine of the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib plus the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Prof. Paolo Ghia, MD, from the College Vita-Salute San Raffaele, in Italy, offered the preliminary outcomes of this research1.
After a median follow-up of 31.6 months, the general response fee was 100% and the entire remission (CR) plus CR with incomplete rely restoration fee was 48%. Importantly, the perfect undetectable minimal residual illness (<10-4) fee was 59% in not less than one peripheral blood pattern. Lastly, the median progression-free survival was not reached at this level. The estimated 24-month progression-free survival fee was 94%.
COVID-19 (55%), diarrhea (39%), nausea (30%), contusion (29%), and fatigue (23%) have been essentially the most continuously noticed unwanted effects with the mix routine. “The security profile was total favorable and we didn’t see any sudden points,” commented Prof. Ghia.
In conclusion, zanubrutinib plus venetoclax delivered promising preliminary efficacy leads to newly identified CLL/SLL in individuals with del(17p) and/or TP53 mutations.
Medical writing assist was offered by Robert van den Heuvel.
Copyright ©2024 Medicom Medical Publishers
